Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Corea y enfermedad de Huntington Chorea & Huntington’s disease 108 artículos Viendo del 1 al 40 de 108 artículos
Pub MED

Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes.NUEVO

McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ; Track-On HD Investigators..
Biol Psychiatry. 2018 Mar 1;83(5):456-465. doi: 10.1016/j.biopsych.2017.10.019. Epub 2017 Oct 26.
Pub MED

A systematic linguistic profile of spontaneous narrative speech in pre-symptomatic and early stage Huntington's disease.NUEVO

Hinzen W, Rosselló J, Morey C, Camara E, Garcia-Gorro C, Salvador R, de Diego-Balaguer R.
Cortex. 2018 Mar;100:71-83. doi: 10.1016/j.cortex.2017.07.022. Epub 2017 Aug 9.
Pub MED

Progressive microstructural changes of the occipital cortex in Huntington's disease.NUEVO

Odish OFF, Reijntjes RHAM, van den Bogaard SJA, Roos RAC, Leemans A.
Brain Imaging Behav. 2018 Feb 28. doi: 10.1007/s11682-018-9849-5. [Epub ahead of print]
Pub MED

Are immunotherapies for Huntington's disease a realistic option?NUEVO

Denis HL, Lauruol F, Cicchetti F.
Mol Psychiatry. 2018 Feb 27. doi: 10.1038/s41380-018-0021-9. [Epub ahead of print] Review.
Pub MED

Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers.NUEVO

van Duijn E, Vrijmoeth EM, Giltay EJ, Bernhard Landwehrmeyer G; REGISTRY investigators of the European Huntington's Disease Network..
J Affect Disord. 2018 Mar 1;228:194-204. doi: 10.1016/j.jad.2017.11.074. Epub 2017 Nov 15.
Pub MED

Closing-in Phenomenon in Huntington's Disease: A Neuropsychological Marker of Frontal/Executive Dysfunction.NUEVO

De Lucia N, Peluso S, Roca A, Russo CV, Massarelli M, De Michele G, Di Maio L, Salvatore E, De Michele G.
Arch Clin Neuropsychol. 2018 Mar 15. doi: 10.1093/arclin/acy020. [Epub ahead of print]
Pub MED

Neurocardiovascular pathology in Premanifest and Early Stage Huntington's Disease.NUEVO

Bellosta Diago E, Pérez-Pérez J, Santos Lasaosa S, Viloria Alebesque A, Martínez-Horta S, Kulisevsky J, López Del Val J.
Eur J Neurol. 2018 Mar 14. doi: 10.1111/ene.13630. [Epub ahead of print]
Pub MED

A critical review of brain and cognitive reserve in Huntington's disease.NUEVO

Soloveva MV, Jamadar SD, Poudel G, Georgiou-Karistianis N.
Neurosci Biobehav Rev. 2018 Mar 11;88:155-169. doi: 10.1016/j.neubiorev.2018.03.003. [Epub ahead of print] Review.
Pub MED

Neuromuscular synapse degeneration without muscle function loss in the diaphragm of a murine model for Huntington's Disease.NUEVO

Valadão PAC, Gomes MPSM, Aragão BC, Rodrigues HA, Andrade JN, Garcias R, Joviano-Santos JV, Luiz MA, Camargo WL, Naves LA, Kushmerick C, Cavalcante WLG, Gallacci M, de Jesus ICG, Guatimosim S, Guatimosim C.
Neurochem Int. 2018 Mar 10;116:30-42. doi: 10.1016/j.neuint.2018.03.007. [Epub ahead of print]
Pub MED

Huntingtin protein: A new option for fixing the Huntington's disease countdown clock.NUEVO

Caterino M, Squillaro T, Montesarchio D, Giordano A, Giancola C, Melone MAB.
Neuropharmacology. 2018 Mar 8;135:126-138. doi: 10.1016/j.neuropharm.2018.03.009. [Epub ahead of print] Review.
Pub MED

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.NUEVO

Cabezas-Llobet N, Vidal-Sancho L, Masana M, Fournier A, Alberch J, Vaudry D, Xifró X.
Mol Neurobiol. 2018 Mar 10. doi: 10.1007/s12035-018-0972-5. [Epub ahead of print]
Pub MED

Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.NUEVO

Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ.
Sci Rep. 2018 Mar 9;8(1):4260. doi: 10.1038/s41598-018-21788-x.
Pub MED

Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.NUEVO

López-Hurtado A, Burgos DF, González P, Dopazo XM, González V, Rábano A, Mellström B, Naranjo JR.
Mol Brain. 2018 Mar 9;11(1):13. doi: 10.1186/s13041-018-0359-6.
Pub MED

Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.NUEVO

Holley SM, Kamdjou T, Reidling JC, Fury B, Coleal-Bergum D, Bauer G, Thompson LM, Levine MS, Cepeda C.
CNS Neurosci Ther. 2018 Apr;24(4):329-342. doi: 10.1111/cns.12839. Epub 2018 Mar 6. Review.
Pub MED

Exploring emotion regulation and emotion recognition in people with presymptomatic Huntington's disease: The role of emotional awareness.NUEVO

Zarotti N, Simpson J, Fletcher I, Squitieri F, Migliore S.
Neuropsychologia. 2018 Mar 3;112:1-9. doi: 10.1016/j.neuropsychologia.2018.02.030. [Epub ahead of print]
Pub MED

A genetic modifier suggests that endurance exercise exacerbates Huntington's disease.NUEVO

Corrochano S, Blanco G, Williams D, Wettstein J, Simon M, Kumar S, Moir L, Agnew T, Stewart M, Landman A, Kotiadis VN, Duchen MR, Wackerhage H, Rubinsztein DC, Brown SDM, Acevedo-Arozena A.
Hum Mol Genet. 2018 Mar 2. doi: 10.1093/hmg/ddy077. [Epub ahead of print]
Pub MED

A novel ex vivo Huntington's disease model for studying GABAergic neurons and cell grafts by laser microdissection.NUEVO

André EM, Daviaud N, Sindji L, Cayon J, Perrot R, Montero-Menei CN.
PLoS One. 2018 Mar 5;13(3):e0193409. doi: 10.1371/journal.pone.0193409. eCollection 2018.
Pub MED

Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.NUEVO

Cardinale A, Fusco FR.
CNS Neurosci Ther. 2018 Apr;24(4):319-328. doi: 10.1111/cns.12834. Epub 2018 Mar 3. Review.
Pub MED

Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.NUEVO

Winder JY, Roos RAC.
PLoS One. 2018 Mar 1;13(3):e0193866. doi: 10.1371/journal.pone.0193866. eCollection 2018.
Pub MED

A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington's Disease.NUEVO

Yan S, Tu Z, Liu Z, Fan N, Yang H, Yang S, Yang W, Zhao Y, Ouyang Z, Lai C, Yang H, Li L, Liu Q, Shi H, Xu G, Zhao H, Wei H, Pei Z, Li S, Lai L, Li XJ.
Cell. 2018 Mar 23. pii: S0092-8674(18)30285-X. doi: 10.1016/j.cell.2018.03.005. [Epub ahead of print]
Pub MED

Chorea revealing systemic lupus erythematosus in a 13-year old boy: A case report and short review of the literature.NUEVO

Athanasopoulos E, Kalaitzidou I, Vlachaki G, Stefanaki S, Tzagkaraki A, Niotakis G, Tritou I, Ladomenou F.
Int Rev Immunol. 2018 Mar 29:1-6. doi: 10.1080/08830185.2018.1452920. [Epub ahead of print]
Pub MED

Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study.NUEVO

Coppen EM, van der Grond J, Roos RAC.
J Clin Mov Disord. 2018 Mar 23;5:2. doi: 10.1186/s40734-018-0069-3. eCollection 2018.
Pub MED

Reactive Neuroblastosis in Huntington's Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain.NUEVO

Kandasamy M, Aigner L.
Front Cell Neurosci. 2018 Mar 9;12:37. doi: 10.3389/fncel.2018.00037. eCollection 2018.
Pub MED

[Psychiatric symptoms in patients with Huntington's disease].NUEVO

Jensen RN, Bolwig T, Sørensen SA.
Ugeskr Laeger. 2018 Mar 26;180(13). pii: V07160499. Danish.
Pub MED

Transcriptional regulatory networks underlying gene expression changes in Huntington's disease.NUEVO

Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, Bergey DE, Wheeler VC, MacDonald ME, Baliga NS, Rosinski J, Hood LE, Carroll JB, Price ND.
Mol Syst Biol. 2018 Mar 26;14(3):e7435. doi: 10.15252/msb.20167435.
Pub MED

Frontotemporal Dementia and Chorea associated with a Compound Heterozygous TREM2 Mutation.NUEVO

Redaelli V, Salsano E, Colleoni L, Corbetta P, Tringali G, Del Sole A, Giaccone G, Rossi G.
J Alzheimers Dis. 2018 Mar 23. doi: 10.3233/JAD-180018. [Epub ahead of print]
Pub MED

Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala(2)GIP in rat model of Huntington's disease.NUEVO

Verma MK, Goel R, Nandakumar K, Nemmani KVS.
Eur J Pharmacol. 2018 Mar 22;828:31-41. doi: 10.1016/j.ejphar.2018.03.034. [Epub ahead of print]
Pub MED

Quality of life in Huntington's disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life.NUEVO

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development..
Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27317. [Epub ahead of print] Review.
Pub MED

Genetic Counselling and Narrative Practices: A Model of Support following a "Negative" Predictive Test for Huntington's Disease.NUEVO

MacLeod R, Moldovan R, Stopford C, Ferrer-Duch M.
J Huntingtons Dis. 2018 Mar 16. doi: 10.3233/JHD-170276. [Epub ahead of print]
Pub MED

Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's Disease.NUEVO

Thadke SA, Perera JDR, Hridya VM, Bhatt K, Shaikh AY, Hsieh WC, Chen M, Gayathri C, Gil RR, Rule GS, Mukherjee A, Thornton CA, Ly DH.
Biochemistry. 2018 Mar 27. doi: 10.1021/acs.biochem.8b00062. [Epub ahead of print]
Pub MED

The S1P Axis: New Exciting Route for Treating Huntington's Disease.NUEVO

Di Pardo A, Maglione V.
Trends Pharmacol Sci. 2018 Mar 17. pii: S0165-6147(18)30047-6. doi: 10.1016/j.tips.2018.02.009. [Epub ahead of print] Review.
Pub MED

Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease.NUEVO

Fritz NE, Boileau NR, Stout JC, Ready R, Perlmutter JS, Paulsen JS, Quaid K, Barton S, McCormack MK, Perlman SL, Carlozzi NE; Huntington Disease Quality of Life Site Investigators and Coordinators, University of Michigan, University of Iowa, Indiana University, Johns Hopkins University, University of California, Rutgers University, Piscataway, Washington University, Struthers Parkinson’s Center, Cleveland Clinic Foundation, University of California, Northwestern University..
J Neuropsychiatry Clin Neurosci. 2018 Mar 21:appineuropsych17080173. doi: 10.1176/appi.neuropsych.17080173. [Epub ahead of print]
Pub MED

Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.NUEVO

Song H, Li H, Guo S, Pan Y, Fu Y, Zhou Z, Li Z, Wen X, Sun X, He B, Gu H, Zhao Q, Wang C, An P, Luo S, Hu Y, Xie X, Lu B.
Brain. 2018 Mar 28. doi: 10.1093/brain/awy081. [Epub ahead of print]
Pub MED

A Unique Case with Oral Dyskinesia, Chorea, Ataxia, and Mild Cognitive Impairment with Caudate Atrophy and Characteristic Brain Calcifications.NUEVO

Hishikawa N, Fukui Y, Sato K, Takemoto M, Yamashita T, Ohta Y, Abe K.
Intern Med. 2018 Mar 30. doi: 10.2169/internalmedicine.9454-17. [Epub ahead of print]
Pub MED

Evaluation of Cognition and Cortical Excitability in Huntington's Disease.

Kamble N, Netravathi M, Nagaraju BC, Lenka A, Kumar K, Sowmya V, Jain S, Pal PK.
Can J Neurol Sci. 2018 Jan 8:1-6. doi: 10.1017/cjn.2017.277. [Epub ahead of print]
Pub MED

Time-Restricted Feeding Improves Circadian Dysfunction as well as Motor Symptoms in the Q175 Mouse Model of Huntington's Disease.

Wang HB, Loh DH, Whittaker DS, Cutler T, Howland D, Colwell CS.
eNeuro. 2018 Jan 3;5(1). pii: ENEURO.0431-17.2017. doi: 10.1523/ENEURO.0431-17.2017. eCollection 2018 Jan-Feb.
Pub MED

Reconstituting Corticostriatal Network on-a-Chip Reveals the Contribution of the Presynaptic Compartment to Huntington's Disease.

Virlogeux A, Moutaux E, Christaller W, Genoux A, Bruyère J, Fino E, Charlot B, Cazorla M, Saudou F.
Cell Rep. 2018 Jan 2;22(1):110-122. doi: 10.1016/j.celrep.2017.12.013.
Pub MED

Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.

Singh BK, Vatsa N, Nelson VK, Kumar V, Kumar SS, Mandal SC, Pal M, Jana NR.
Mol Neurobiol. 2018 Jan 2. doi: 10.1007/s12035-017-0853-3. [Epub ahead of print]
Pub MED

Stem cell transplantation for Huntington's diseases.

Choi KA, Choi Y, Hong S.
Methods. 2018 Jan 15;133:104-112. doi: 10.1016/j.ymeth.2017.08.017. Epub 2017 Sep 1. Review.
Pub MED

Xeroderma pigmentosum is a definite cause of Huntington's disease-like syndrome.

Garcia-Moreno H, Fassihi H, Sarkany RPE, Phukan J, Warner T, Lehmann AR, Giunti P.
Ann Clin Transl Neurol. 2017 Dec 4;5(1):102-108. doi: 10.1002/acn3.511. eCollection 2018 Jan.
Viendo del 1 al 40 de 108 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.